IL33 and chronic obstructive pulmonary disease: A recent phase 2a trial was completed for the evaluation of itepekimab, an anti–IL-33 monoclonal antibody, in patients with moderate to severe COPD on a stable regimen of triple-inhaled or double-inhaled background maintenance therapy [66].